Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market – Insights
Chronic obstructive pulmonary disease (COPD) involves lung inflammation, causing obstruction of airflow from the lungs. It is a chronic disease and symptoms include difficulty in breathing, mucus formation, wheezing, and others. COPD is a progressive lung disease, which includes chronic bronchitis, emphysema, and refractory asthma. Prime causes behind occurrence of chronic obstructive pulmonary disease include smoking, air pollution, secondhand smoke, alpha-1 deficiency-related emphysema (rare form of COPD), and others. There are certain ways, by which complications can be prevented, as well as disease progression can be slowed down. These may include quitting smoking, adherence to the prescribed medication, and preventing associated co-morbidities such as flu, pneumonia, and others by vaccination against these diseases.
High incidence and prevalence of chronic obstructive pulmonary disease (COPD), coupled with awareness efforts carried out by individual organizations is expected to support global chronic obstructive pulmonary disease (COPD) treatment market growth over the forecast period
According to National Center for Biotechnology Information (NCBI), in 2016, chronic obstructive pulmonary disease (COPD) was the third leading cause of death, globally. Furthermore, according Global Burden of Disease Study, COPD was prevalent in over 300 million people globally in 2013. Moreover, according to the same source, in European adults over 40 years of age, the prevalence of COPD ranged from 15-20%, in 2016. Moreover, according to the World Health Organization (WHO), Global Burden of Disease Study reports prevalence of 251 million cases of COPD, globally, in 2016. Increasing prevalence is expected to support the global chronic obstructive pulmonary disease (COPD) treatment market growth over the forecast period. Organizations such as World Health Organization (WHO), COPD Foundation, American Thoracic Society, and Centers for Disease Control and Prevention (CDC) work towards raising COPD awareness in the population. National Institutes of Health (NIH) runs an initiative, ‘COPD Learn More Breathe Better’, and celebrates November as a national COPD awareness month. These factors are expected to support global chronic obstructive pulmonary disease (COPD) treatment market growth over the forecast period.
The global chronic obstructive pulmonary disease (COPD) treatment market size was valued at US$ 14,209.0 million in 2017, and is expected to witness a robust CAGR of 4.9% over the forecast period (2018–2026).
Figure 1. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), by Region, 2018 & 2026
Source: Coherent Market Insights Analysis (2017)
Ongoing research and development and product launches is expected to support global chronic obstructive pulmonary disease (COPD) treatment market
Verona Pharma commenced a phase IIb clinical trial to assess nebulized ensifentrine (RPL554), in combination with a long-acting bronchodilator to treat moderate to severe COPD, in May 2019. Novartis AG launched Ultibro Breezhaler and Seebri Breezhaler in China for the treatment of COPD, in March 2019. Cipla launched Niveoli, beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler for adults suffering from obstructive airway diseases (OAD) such as asthma and COPD, in April 2019. Moreover, manufacturers are also involved in improving overall COPD treatment paradigm by introducing medical devices, web-based applications, and other efforts to reduce the global burden of chronic obstructive pulmonary disease. For instance, Spire Health launched a study to develop new digital biomarkers that can predict exacerbations—and potentially hospitalizations—in patients with severe COPD, in May 2019. These factors are expected to support global chronic obstructive pulmonary disease (COPD) treatment market growth over the forecast period.
Figure 2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share, by Distribution Channel, 2018 & 2026
However, development of new drugs is a challenging task and drug failures in clinical trials have affected growth of the market. For instance, asthma drug benralizumab failed to decrease annual COPD exacerbation rates for patients with moderate to very severe COPD, in May 2019. The Phase III, randomized, double-blind, placebo-controlled, parallel-group clinical trials GALATHEA and TERRANOVA evaluated the efficacy and safety of benralizumab for the prevention of exacerbations in patients with moderate to very severe COPD.
Some major players operating in the global chronic obstructive pulmonary disease (COPD) treatment market include AstraZeneca Plc, Orion Corporation, Mylan N.V., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc., and CHIESI Farmaceutici SpA
Chronic obstructive pulmonary disease (COPD) presents itself with mild, moderate, and severe symptoms. Treatment of chronic obstructive pulmonary disease (COPD) involves stepwise non-pharmacological and pharmacological interventions. Non-pharmacological interventions include risk reduction (smoking cessation) and preventing and treating co-morbidities (cardiovascular disease, anxiety, depression, and others). Pharmacological interventions include prescribing short acting bronchodilators, long acting bronchodilators, and others.
Factors such as awareness initiatives by organizations, increasing prevalence of COPD, and product launches is supporting the global chronic obstructive pulmonary disease (COPD) treatment market growth. For instance, in May 2019, Boehringer Ingelheim and Optimum Patient Care announced the creation of a new patient registry, APEX COPD, to better understand COPD and how it can be typically treated in primary care offices. Such initiatives by industry players are expected to boost global chronic obstructive pulmonary disease (COPD) treatment market over the forecast period. Moreover, pipeline for respiratory diseases and mainly COPD has several potential medications, which is expected to drive global chronic obstructive pulmonary disease (COPD) treatment market growth.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 26 market data tables and 32 figures on "Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Global forecast to 2026”.
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.